Cancer Drugs Fund receives boost but will no longer fund “overpriced” drugs = BMJ
Cancer Drugs Fund receives boost but will no longer fund “overpriced” drugsBMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g5382 (Published 01 September 2014)Cite this as: BMJ 2014;349:g5382Nigel HawkesThe Cancer Drugs Fund has been given a 40% increase in funding and has agreed to remove from its list any drugs that are overpriced or produce little clinical benefit. The fund’s chairman also promised to try to align the fund’s assessments more closely with those of the National Institute for Health and Care Excellence (NICE).NHS England, which is responsible for the drugs fund, has agreed to increase the amount th...
Source: PharmaGossip - September 1, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
How To Motivate Off-Label Promotion? Gives Reps Trays Of $50 Bills
Three years ago, a former Cephalon manager filed a whisteblower lawsuit over alleged illegal marketing of two drugs – the Treanda treatment for chronic lymphocytic leukemia and the Fentora painkiller – prompting the US Attorney in New York to open an investigation into the drugmaker, which is now owned by Teva Pharmaceutical.
Now, though, further details are emerging about the extent to which Cephalon executives allegedly conspired to use questionable studies and off-label marketing tactics to boost sales of Treanda, in particular. The allegations, which were made by a former Cephalon employee listed as 'John Doe...
Source: Pharmalot - June 20, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
